Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Clin Pharmacol Ther. 2014 Apr 29;96(2):182–191. doi: 10.1038/clpt.2014.93

Table 1.

Patient characteristics

Number of patients (%)
Arm A
(fixed dose)
Arm B
(dose adjusted)
All
(A + B)
Number of enrolled patients 28 27 55
Men 17 (60.7) 14 (51.9) 31 (56.4)
Age (years)
  Median 63 59 62
  Range 29–83 37–96 29–96
Weight (Kg)
  Mean 75.8 72.5 74.2
  Standard Deviation 15.2 13.7 14.4
Performance Status
  0 7 (25.0) 6 (22.2) 13 (23.6)
  1 14 (50.0) 17 (63.0) 31 (56.4)
  2 7 (25.0) 4 (14.8) 11 (20.0)
Histologic cell type
  Adenocarcinoma 15 (53.6) 17 (63.0) 32 (58.2)
  Squamous 7 (25.0) 5 (18.5) 12 (21.8)
  NSC not otherwise classified 5 (17.9) 2 (7.4) 7 (12.7)
  Adenosquamous 0 1 1
  Large cell neuroendocrine 1 1 2
  Sarcomatoid 0 1 1
Prior Chemotherapy
  No 4 (14.3) 4 (14.8) 8 (14.5)
  1 regimen 19 (67.9) 15 (55.6) 34 (61.8)
  2 regimens 5 (17.9) 8 (29.6) 13 (23.6)
Previous radiation therapy 11 (39.3) 11 (40.7) 22 (40.0)
Smoking Status
  Current 8 (28.6) 13 (48.1) 21 (38.2)
  Former 15 (53.6) 14 (51.9) 29 (52.7)
  Never 5 (17.9) 0 (0) 5 (9.1)